Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
144
resultados
Última actualización
07/05/2025 [07:12:00]
Resultados 75 a 100 de 144
Resumen de: CN119120778A
The invention relates to the technical field of virus detection, and particularly discloses a method for detecting a chicken infectious bursal disease virus based on RAA-CRISPR/Cas13a-LFD. The sequence of the upstream primer for detecting the infectious bursal disease virus is as shown in SEQ ID NO: 1, the sequence of the downstream primer is as shown in SEQ ID NO: 2, and the sequence of the specific crRNA is as shown in SEQ ID NO: 3. According to the method provided by the invention, the target gene can be effectively amplified by reacting for 40 minutes under the condition of 37 DEG C, and a test result can be judged through LFD naked eye observation; the specificity is good, and the lowest detection limit can reach 100 copies/mu L; good repeatability and stability are realized; the coincidence rate of clinical detection reaches 98.33%, and the kit can be used for clinical rapid diagnosis and prevention and control of the infectious bursal disease (IBD).
Resumen de: WO2024252368A2
The invention provides methods and compositions related to methods for determining whether a human subject having ulcerative colitis will respond to treatment with a humanized antibody having binding specificity for human α4β7 integrin for treating ulcerative colitis. The invention provides response markers that can be used to identify responders of ulcerative colitis.
Resumen de: WO2024252267A1
The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.
Resumen de: AU2024266697A1
Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
Resumen de: CN119104708A
The invention discloses application of kynurenine, formyl-5-hydroxykynurenine and 3-methoxy-4-hydroxyphenyl glycol as serum biomarkers for evaluating the curative effect of Crohn's disease, and relates to the technical field of medical treatment. In particular to application of kynurenine, formyl-5-hydroxykynurenine and 3-methoxy-4-hydroxyphenyl glycol as serum markers in preparation of a kit for evaluating the treatment effect of the mesenchymal stem cells on the Crohn disease. On the basis of an isotope labeled liquid chromatography-mass spectrometry technology, the therapeutic effectiveness biomarker is screened by detecting the change of serum metabolites before and after the placenta-derived mesenchymal stem cells treat a mouse with Crohn disease, and the diagnostic efficiency of the therapeutic effectiveness biomarker is evaluated; and data support is provided for clinical transformation of the mesenchymal stem cells for treating Crohn's disease.
Resumen de: CN119097714A
本发明提供了促炎基质4细胞抑制剂和检测MMP1的物质的应用，属于生物医药技术领域。其中，所述促炎基质4细胞抑制剂可用于制备治疗肠上皮再生障碍、先天性巨结肠、小肠结肠炎或先天性巨结肠相关小肠结肠炎的药物。所述检测MMP1的物质可用于制备预测先天性巨结肠相关小肠结肠炎的产品。本发明首次发现了促炎基质4细胞在先天性巨结肠患者的扩张段肠组织中表现出特异性，而这些细胞无法维持健康类器官的生长；然而，通过使用促炎基质4细胞抑制剂，可以恢复上皮类器官的生长。此外，促炎基质4细胞的出现在先天性巨结肠相关小肠结肠炎发作之前，这为预测和治疗该疾病提供了有力的依据。因此本发明在生物医药技术领域具有广泛的应用前景。
Resumen de: MX2024013561A
Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation. Described herein are compositions and methods that, in some embodiments, are specifically configured to treat different types of constipation. In particular, described herein are compositions and methods for treating IBS-C, opioid induced constipation, and chronic idiopathic constipation. In addition to treating the symptom of constipation, these embodiments of the compositions and methods described herein are configured to address specific etiologies and/or pathophysiologies associated with the constipation types of IBS-C, opioid induced constipation, and chronic idiopathic constipation.
Resumen de: CN119086926A
本发明涉及CLCA1蛋白作为表征双歧杆菌丰度的标志物的应用，还涉及一种表征双歧杆菌丰度的方法，其通过检测样本中的CLCA1蛋白水平从而评估双歧杆菌的丰度。本发明基于宿主肠道蛋白CLCA1和双歧杆菌属细菌细胞膜上的atpH蛋白特异性互作从而促进双歧杆菌的定植的作用机制，首次提出通过检测粪便中CLCA1的丰度来间接反应肠道双歧杆菌的丰度，该方法具有快速、便捷、无需基因组DNA提取步骤、对人员设备要求较低并且成本低的优势；此外，通过检测疑似患者粪便中CLCA1的丰度，可为与肠道双歧杆菌的丰度降低相关的疾病的诊疗提供一定的参考依据。
Resumen de: CN119074963A
The invention relates to the technical field of relieving of hepatotoxicity caused by triptolide, particularly provides a method for reducing hepatotoxicity induced by triptolide based on ergothioneine, and provides application of ergothioneine in preparation of drugs for reducing hepatotoxicity of triptolide. According to the application disclosed by the invention, medicinal compositions, namely triptolide and ergothioneine, are jointly used on a dextran sulfate sodium salt induced inflammation animal model, so that colon and liver tissues in the inflammation animal model are analyzed. The result shows that the ergothioneine does not interfere with the drug effect of the triptolide, and the hepatotoxicity induced by the triptolide can be obviously improved; the ergothioneine disclosed by the invention has a guiding effect on inflammatory bowel diseases, lupus nephritis, asthma, rheumatoid arthritis, nephrotic syndrome, eczema, psoriasis or tumors which are treated by triptolide.
Resumen de: US2024397984A1
Provided are food and drink ingredients produced from wheat grain which has a low level (2-30%) of total starch branching enzyme II activity and an amylose content in the starch of at least 50% (w/w), and processes for producing and using the ingredients. Also provided are foods produced from the ingredients which may be used in humans to improve one or more parameters of metabolic health, bowel health or cardiovascular health.
Resumen de: WO2024246589A1
The invention relates to an isolated antibody or a fragment thereof that binds to the SKECF peptide of the sST2 protein. In particular, the invention relates to a short variable fragment of an antibody (scFv) and to a human antibody with affinity for the sST2 molecule, to nucleic acids encoding the same, to the pharmaceutical compositions containing the same, and to the use thereof to treat inflammatory diseases, such as ulcerative colitis.
Resumen de: WO2024243687A1
Methods of selecting prebiotics, optionally resistant starch, optimized for an individual with inflammatory bowel disease and methods of treating individuals with the selected prebiotics are provided.
Resumen de: US2024400694A1
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
Resumen de: JP2024169624A
To provide a method for inspecting ulcerative colitis which is useful for determining a disease state of ulcerative colitis.SOLUTION: A method for producing a strain sample derived from a subject in which the strain diversity and/or the number of strains in the sample of the subject are maintained includes: 1) a process of adding the sample of the subject to a culture medium; 2) a process of performing an operation to bring pH of the culture medium to 6.2 to 6.7 in starting the cultivation if necessary; and 3) a process of culturing the sample after starting the cultivation without performing an operation intended to maintain pH of the culture medium. Preferably, the method includes A) a process of performing sterilization of the culture medium and aeration to anaerobic gas and/or B) a process of suspending the sample to ascorbic acid-added phosphate buffer, before 1).SELECTED DRAWING: Figure 1
Resumen de: WO2023141097A1
Disclosed are methods for treating active eosinophilic colitis (EoC), or in certain aspects, inflammatory bowel disease (IBD), in an individual in need thereof. In one aspect, the methods may comprise a) assaying a tissue sample obtained from a colon of an individual who may be in need of such treatment, wherein the assaying comprises detecting expression of one or more gene of a transcriptome gene set; b) calculating a score based on the expression of one or more gene of a transcriptome gene set; and c) selecting a tissue sample that exhibits a score indicative of EoC or IBD. The methods may further comprise administering an EoC or IBD therapy to the individual whose tissue sample exhibited a score indicative of having EoC or IBD.
Resumen de: CN119061137A
The invention discloses an eRNA molecular marker for auxiliary diagnosis of Crohn's disease and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA42767, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention also provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of Crohn's disease, and the kit comprises an eRNA42767 fluorescent quantitative PCR specific amplification primer, the nucleotide sequence of the upstream amplification primer is 5 '-CCTCTCTCTGGACATGCCTA-3', and the nucleotide sequence of the downstream amplification primer is 5 '-CCTATGCGTAGAGATTCTTGCC-3'. The kit has the advantages that early diagnosis of a patient suffering from the Crohn disease on the molecular level is conveniently, quickly and efficiently realized, the pertinence is strong, the specificity is strong, the sensitivity is high, and the kit is beneficial to early discovery and timely treatment of the Crohn disease.
Resumen de: CN119061105A
The invention discloses a research method for promoting ulcerative colitis barrier repair mechanism by using butyric acid to activate intestinal epithelial autophagy, and relates to the field of digestive systems.The research method comprises the following steps that S1, a clinical sample is collected and analyzed; s2, animal model construction and experiment; s3, carrying out cell experiment verification; according to the research method for promoting the barrier repair mechanism of ulcerative colitis by activating intestinal epithelial autophagy through butyric acid, the influence of butyric acid on intestinal epithelial autophagy and barrier functions in UC patients and animal models is systematically researched, the new mechanism of promoting UC barrier repair by activating ATG16L1 related autophagy pathways through butyric acid is disclosed, a new theoretical basis is provided for UC treatment, and the research method has wide application prospects. By deeply researching the regulation and control mechanism of butyric acid on ATG16L1 related autophagy, accurate diagnosis and personalized treatment of UC can be realized, that is, a proper treatment scheme is selected according to the specific condition of a patient, so that the treatment effect is improved, and the unnecessary medical expenditure is reduced.
Resumen de: CN119039421A
The invention discloses a CLDN-10b spliceosome polypeptide as shown in SEQ ID: 1, a CLDN-10b mutant polypeptide as shown in SEQ ID: 2, an antibody capture device containing the polypeptides as shown in SEQ ID: 1 and SEQ ID: 2, a kit and a detection method, and belongs to the technical field of immunology. According to the technical scheme, CLND-10b polypeptide containing SEQ ID: 1 and SEQ ID: 2 is cloned and expressed, an antibody in a sample is captured through a solid-phase carrier and the polypeptide contained on the solid-phase carrier, and the effect of auxiliary diagnosis of the inflammatory bowel disease-psoriasis co-disease is achieved.
Resumen de: US2024393333A1
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Resumen de: US2024392375A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease (IBD).
Resumen de: US2024389885A1
Described herein are methods of utilizing single fasting methane breath concentrations to monitor, select treatment for, and to treat subjects having intestinal methanogen overgrowth.
Resumen de: US2024392374A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease. Disclosed is a method of differentiating between ulcerative colitis (UC) and Crohn's disease (CD) in a subject having an inflammatory bowel disease (IBD) comprising determining a level of one or more of SEQ ID NOs: 1-590 in a sample from the subject.
Resumen de: WO2024240709A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: US2024391994A1
The present disclosure is generally relates to methods of treating ulcerative colitis. The methods are particularly suitable for treating bowel urgency a specific sub-group of patients with ulcerative colitis and having bowel urgency.
Nº publicación: US2024395384A1 28/11/2024
Solicitante:
PROMETHEUS LABORATORIES INC [US]
Prometheus Laboratories Inc
Resumen de: US2024395384A1
Provided are systems and methods for treating an immune-mediated inflammatory disease (e.g., inflammatory bowel disease) in a subject or selecting the subject for treatment, based on an estimated time to remission following induction of an anti-TNF therapy calculated by a patient-centric precision model.
BOPI
Sede Electrónica
